secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274216
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Q3 net loss $8.2M; FDA BTD for TA-ERT; $50M placement; BLA on track Q1 2026
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation for TA-ERT (MPS IIIB); BLA submission on track for Q1 2026.
- Completed $50M private placement in Oct 2025; cash plus proceeds expected to fund ops into Q4 2026.
- Q3 2025 net loss $8.2M vs $8.7M YoY; R&D $5.0M (down 24% YoY) due to tildacerfont program cessation.
- Cash $10.7M at Sep 30, 2025; common shares 563,491 pre-placement; Oct placement added 502,181 shares and 233,144 prefunded warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000119312525274216/0001193125-25-274216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000119312525274216/sprb-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer